Výsledky vyhledávání - "Vincent A DiPippo"

Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma

Autor: Camilo Jimenez, Bennett B Chin, Richard B Noto, Joseph S Dillon, Lilja Solnes, Nancy Stambler, Vincent A DiPippo, Daniel A Pryma

Publikováno v: Endocrine-related cancer. 30(2)

The objective of this study is to present the complete biomarker response dataset from a pivotal trial evaluating the efficacy and safety of high-specific-activity I-131 meta-iodobenzylguanidine in patients with advanced pheochromocytoma or paragangl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::567edd8e57d3398acb72b3132cf89617
https://pubmed.ncbi.nlm.nih.gov/36472300

Zobrazit plný text záznamu

Early outcomes from lutetium Lu-177 vipivotide tetraxetan treatment in patients selected for therapy with piflufolastat F-18 PET imaging

Autor: Thomas Pence Boike, Vincent A. DiPippo, Heather Austin, Wendy Turnquist, Yusuf Qamruzzaman

Publikováno v: Journal of Clinical Oncology. 41:191-191

191 Background: The Vision trial utilized Ga 68 PSMA 11 imaging to select patients for treatment with Lutetium Lu 177 Vipivotide Tetraxetan. Current guidelines allow not only Ga 68 PSMA 11 PET but also Piflufolastat F 18 PET when selecting patients f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a92c2ca8f2d0d14f521ef31ff8c48a41
https://doi.org/10.1200/jco.2023.41.6_suppl.191

Zobrazit plný text záznamu

Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study

Autor: Frederic Pouliot, Michael A. Gorin, Steven P. Rowe, Lawrence Saperstein, Bela Stephen Denes, Vincent A. DiPippo, Nancy Stambler, Michael J. Morris, Barry A. Siegel

Publikováno v: Journal of Clinical Oncology. 41:61-61

61 Background: Piflufolastat F 18 is a PSMA-targeted radiopharmaceutical approved in the US for imaging prostate cancer (PCa) patients both at the time of initial staging and at disease recurrence. In a phase 3 study of patients with biochemically re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ae167496d242d3c21c54d1adf00a618
https://doi.org/10.1200/jco.2023.41.6_suppl.61

Zobrazit plný text záznamu

SAT-163 Status at 10 Years: Long-Term Follow-Up for a Phase 2a Study of High-Specific-Activity (HSA) I 131 Iobenguane in Patients (Pts) with Relapsed/Refractory High-Risk Neuroblastoma

Autor: Vincent A. DiPippo, Judith G. Villablanca, Duo Zhou, John M. Maris, Nancy Stambler, Katherine K. Matthay

Publikováno v: Journal of the Endocrine Society

Background: Metaiodobenzylguanidine (MIBG; iobenguane), a guanethidine derivative, is a substrate for norepinephrine reuptake transporter which is highly expressed on the surface of neuroblastoma cells. AZEDRA® (HSA I-131 MIBG) has been approved by

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d2b3bd76106817de918abd177ac4b65
https://doi.org/10.1210/jendso/bvaa046.1293

Zobrazit plný text záznamu

OR25-07 A Multi-Center, Open-Label, Pivotal Phase 2 Study of Azedra® (HSA I-131-MIBG) in Patients with Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma: Updated Long-Term Survival and Safety

Autor: Richard B. Noto, Vivien Wong, Lilja Solnes, Joseph S. Dillon, Camilo Jimenez, Daniel A. Pryma, Nancy Stambler, Bennett B. Chin, Vincent A. DiPippo

Publikováno v: Journal of the Endocrine Society

Background: Pheochromocytoma/Paraganglioma (PPGL) are rare neuroendocrine tumors with a 5-yr survival rate as low as 12%. There is a high unmet medical need for effective treatment options for patients with advanced disease. AZEDRA®, a high-specific

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23aef196dcd7159161f96c47e82813bb
https://doi.org/10.1210/jendso/bvaa046.1241

Zobrazit plný text záznamu

Biochemical Tumor Marker Status and Its Role in Treatment Response in Patients Who Received High-Specific-Activity I-131 MIBG in Advanced Pheochromocytoma and Paraganglioma (PPGL): Results From a Pivotal Phase 2 Clinical Trial

Autor: Bennett B. Chin, Richard B. Noto, Vincent A. DiPippo, Lilja Solnes, Joseph S. Dillon, Daniel A. Pryma, Camilo Jimenez, Nancy Stambler, Richard A Noto

Publikováno v: Journal of the Endocrine Society

Background: High-specific-activity iodine-131 meta-iodobenzylguanidine (HSA I-131 MIBG; AZEDRA®) has been approved for the treatment of adult and pediatric patients (pts) 12 years and older with iobenguane scan positive, unresectable, locally advanc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b3e0b59faf03ef0601f9402075a5995
https://doi.org/10.1210/jendso/bvab048.333

Zobrazit plný text záznamu

SUN-345 Safety Analysis of High-Specific-Activity I-131 MIBG (AZEDRA®) in Patients with Iobenguane Scan Positive Cancers

Autor: Stuart Apfel, Ravinder K. Grewal, Vivien Wong, Daniel A. Pryma, Tess Lin, Jessica Jensen, Syed S. Mahmood, Miguel Hernandez Pampaloni, Gregory Ravizzini, Bennett B. Chin, Katherine K. Matthay, Vincent A. DiPippo, Nancy Stambler, Theresa White, Camilo Jimenez

Publikováno v: Journal of the Endocrine Society

Introduction: Iobenguane scan positive cancers including pheochromocytoma/paraganglioma (PPGL), neuroblastoma, and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are heterogeneous tumors that arise from neuroendocrine cells. Recently, high-s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77476d9b33a0bf96fffc2d188729bcb9
https://doi.org/10.1210/js.2019-sun-345

Zobrazit plný text záznamu

Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer

Autor: Robert L. Vessella, Eva Corey, Holly M. Nguyen, Lisha G. Brown, Vincent A. DiPippo, William C. Olson

Publikováno v: The Prostate. 76:325-334

BACKGROUND Despite multiple new therapies available to patients with advanced castration-resistant prostate cancer (CRPC), the overall survival benefit still remains relatively short. Therefore, it is important to investigate additional treatment opt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5fb699764757ec7bf5a50b857d6a1a07
https://doi.org/10.1002/pros.23124

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání